Skip to main content
. Author manuscript; available in PMC: 2016 Oct 15.
Published in final edited form as: Cancer Res. 2015 Aug 6;75(20):4384–4397. doi: 10.1158/0008-5472.CAN-15-0457

Figure 7. Analysis of miR-221-222 and PUMA mRNA expression in MM cells from patients.

Figure 7

(A) PUMA mRNA expression is inversely correlated with miR-221 expression in MM cells; analysis based on published data set GSE16558 (p = 0.001). (B) miR-221-222 levels are associated with lower PUMA mRNA levels in MM cells from patients with refractory disease. (C) Inverse correlation between miR-221-222 and PUMA protein expression by LNA-ISH and immunohistochemical analysis of BM biopsies from MM patients with newly diagnosed or refractory disease. Two representative cases are shown, new (MM2) and refractory myeloma (MM10). (D) Schematic model for upregulation of the pro-apoptotic protein PUMA by anti-miR-221-222 therapy in MM. Anti-mR-221-222 therapy, by increasing the level of PUMA, which is downstream of GR and p53, may abrogate drug reistance associated with p53 inactivation and decreased GR expression.